Breakthrough Designation in ALL, HIFU FDA Approval, Breast Cancer Screening Update, and More

Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.

The FDA approved talazoparib plus enzalutamide for HRR-positive, metastatic androgen pathway modulation–naive or -sensitive prostate cancer.

The FDA granted breakthrough therapy designation to enzomenib for relapsed/refractory acute leukemia with a KMT2A rearrangement.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.

Adding darolutamide to androgen deprivation and primary or salvage radiation lowered metastasis risk in very high-risk localized prostate cancer.

The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.